Effect of lipophosphonoxins on inhibition of bacterial colonization of bone cements
Authors:
R. Večeřová 1; K. Bogdanová 1; D. Rejman 2; J. Gallo 3; M. Kolář 1
Authors‘ workplace:
Ústav mikrobiologie LF UP v Olomouci
1; Ústav organické chemie a biochemie AV ČR v. v. i.
2; Ortopedická klinika FNOL a LF UP v Olomouci
3
Published in:
Epidemiol. Mikrobiol. Imunol. 65, 2016, č. 3, s. 171-176
Category:
Original Papers
Overview
Objective:
The study aimed at determining the ability of lipophosphonoxin DR5026 to inhibit the formation of bacterial biofilm on the bone cement surface and assessing potential development of bacterial resistance.
Material and methods:
Bone cement (Hi-Fatigue Bone Cement 2x40, aap Biomaterials GmbH, Germany) was polymerized with lipophosphonoxin DR5026. Cement samples were cultured using bacterial suspension containing Staphylococcus epidermidis CCM7221 at an inoculum density of 106 CFU/mL. After three, 24, and 48 hours of incubation at 35 °C, the number of bacteria adhered to the sample was measured and their growth curve was plotted. In 14 cycles, strains of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, and Streptococcus agalactiae were exposed to subinhibitory concentrations of DR5026 and the minimum inhibitory concentrations (MICs) were determined.
Results:
After three hours of culture in the bacterial inoculum with an initial concentration of 106 CFU/mL, the number of colonies isolated from the cement sample treated with DR5026 was smaller by two orders of magnitude when compared to a control cement sample. After 24 and 48 hours of incubation, the number of CFU remained at 50 in the treated cement, whereas 109 CFU were cultured from control cement samples. The plotted growth curves for bacteria adhered to cements clearly showed the inhibitory effect of lipophosphonoxin on their growth and multiplication, particularly after 48 hours. Following 14 cycles of repeated exposure to subinhibitory concentrations of DR5026, no increase in MICs was noted in the tested strains.
Conclusion:
Lipophosphonoxin DR5026 used to treat bone cement was found to have antibacterial effects and to inhibit the formation of bacterial biofilm. Repeated exposure of the tested bacteria to subinhibitory concentrations of the above lipophosphonoxin did not induce their resistance or increase their MICs.
Key words:
bone cement – joint replacement infections – lipophosphonoxins – antibacterial effect – biofilm
Sources
1. Alt V. In vitro testing of antimicrobial activity of bone cement. Antimicrob Agents Chemother, 2004; 48(11): 4084–4088.
2. Anagnostakos K, Kelm J. Enhancement of antibiotic elution from acrylic bone cement. J Biomed Mater Res B Appl Biomater, 2009; 90(1): 467–475.
3. Arora M, Chan EKS, Gupta S, et al. Polymethylmethacrylate bone cements and additives: A review of the literature. World J Orthop, 2013; 4(2): 67–74.
4. Bistolfi A, Massazza G, Verne E, et al. Antibiotic-loaded cement in orthopaedic Surgery: A review. ISRN Orthopaedics, 2011; 2011: 8 pages. doi:10.5402/2011/290851.
5. Buchholz HW, Engelbrecht H. Über die Depotwirkung einiger Antibiotica bei Vermischung mit dem Kunstharz Palacos. Chirurg, 1970; 41: 511–515.
6. Christensen GD, Simpson WA, Younger JJ, et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol, 1985; 22 (6): 996–1006.
7. Corona PS, Espinal L, Rodriguéz-Pardo D, et al. Antibiotic susceptibility in gram-positive chronic joint arthroplasty infections: Increased amminoglycoside resistance rate in patients with prior aminoglycoside-impregnated cement spacer use. J Arthroplasty, 2014; 28(8): 1617–1621.
8. Gallo J, Bogdanová K, Šiller M et al. Mikrobiologické a farmakologické vlastnosti kostního cementu VancogenX. Acta Chir Orthop Traumatol Cech, 2013; 80: 69–76.
9. Gallo J, Holinka M, Moucha C. Antibacterial surface treatment for orthopaedic implants. Int J Sci, 2014; 15: 13849–13880.
10. Gallo J, Kolar M, Dendis M, et al. Culture and PCR analysis of joint fluid in the diagnosis of prosthetic joint infection. New Microbiol, 2008; 154: 97–104.
11. Gullberg E, Cao S, Berg OG, Ilback C, et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog, 2011; 7(7): e1002158.
12. Hanulík V, Htoutou Sedláková M, Petrželová J, et al. Možnosti flourochinolonů v současné klinické praxi. Klin Farmakol a Farm, 2010; 24(4): 184–186.
13. Hope PG, Kristinsson KG, Norman P, et al. Deep infection of cemented total hip arthroplasties caused by coagulase negative staphylococci. J Bone Joint Surg Br, 1989;71: 851–855.
14. Isenberg HD. Clinical microbiology procedures handbook – 2nd ed. Washington: ASM Press; 2004.
15. Jindrák V, Urbášková P, Nyč O. Fluorochinolony – kriticky ohrožená skupina antibiotik. Practicus, 2007; 6: 6–11.
16. Jiranek WA, Hansen AD, Greenwald AS. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. J Bone Joint Surg Am, 2006; 88(11): 2487–2500.
17. Kühn KD. Release of active ingredients. In: Kühn KD. Bone cements. Berlin: Springer; 2000. s. 253–258.
18. Meyer J, Piller G, Spiegel CA et al. Vacuum-mixing significantly changes antibiotic elution characteristics of commercially available antibiotic-impregnated bone cements. J Bone Joint Surg Am, 2011; 93(22): 2049–2056.
19. Proček T, Ryšková L, Kučera T. Zhodnocení významu ready-made spaceru s gentamicinem ve vztahu k bakteriologickým nálezům u pacientů s infekcí kloubní náhrady. Epidemiol Mikrobiol Imunol, 2014; 63 (2): 142–148.
20. Pulido L, Ghanem E, Joshi A et al. Periprosthetic joint infection, the incidence, timing and predisposing factors. Clin Orthop Relat Res, 2008; 446: 1710–1715.
21. Rejman D, Rabatinova A, Pombinho AR et al. Lipophosphonoxins: new modular molecular structures with significant antibacterial properties. J Med Chem, 2011; 54(22): 7884–7898.
22. Rosenberg I. Chemie fosfonátových analogů nukleotidů a oligonukleotidů – stručná reminiscence a současnost. Chem Listy, 2014; 108: 375–386.
23. Růžička F, Holá V, Votava M. Možnosti průkazu tvorby biofilmu v rutinní mikrobiologické praxi. Epidemiol. Mikrobiol. Imunol, 2006; 55 (1): 23–29.
24. Shuman EK, Urqhart A, Malani PN. Management and prevention of prosthetic joint infection. Infect Dis Clin North Am, 2012; 26: 29–39.
25. Stepanovic S, Vukovic D, Holá V, et al. Quantification of biofilm in microtiter plates: overview of conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS, 2007; 115: 891–899.
26. Suk DH, Rejman D, Dykstra CC, et al. Phosphonoxins: rational design and discovery of a potent nucleotide anti-Giardia agent. Bioorg Med Chem Lett, 2007; 17: 2811–2816.
27. Tande AJ, Patel R. Prosthetic Joint Infection. Clin Microbiol Rev, 2014; 27: 302–345.
28. Trippel SB. Antibiotic-impregnated cement in total joint arthroplasty. J Bone St Surg Am, 1986; 68: 129–302.
29. Urbášková P. Diluční metody – obecný postup. In: Urbášková P. Rezistence bakterií k antibiotikům – vybrané metody. Praha: TRIOS; 1998. S. 1.3–1.7.
30. Votava M. Růst bakterií v podobě biofilmu. In: Votava M. Lékařská mikrobiologie obecná. Brno-Jundrov: Neptun; 2005. s. 57.
31. Witso E. The rate of prosthetic joint infection is underestimated in the arthroplasty registers. Acta Orthopaedica, 2015; 86(3): 277–278.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
![Issue 3](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/fb1e7543e0d855b7cbc7688bc2e14a2a.jpeg)
2016 Issue 3
Most read in this issue
- Stenotrophomonas maltophilia as the cause of ventilator-associated pneumonia in a female patient with toxic epidermal necrolysis and Clostridium colitis: time for off-label tigecycline?
- Avidity of selected autoantibodies – usefulness of their determination for clinical purposes
-
The occurrence of Ixodes ricinus ticks and important tick-borne pathogens in areas with high tick-borne encephalitis prevalence in different altitudinal levels of the Czech Republic
Part II. Ixodes ricinus ticks and genospecies of Borrelia burgdorferi sensu lato complex - HIV/AIDS epidemics in sub-Saharan regions in the 2010s: Regional analysis of UNAIDS data